Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bridge Pharma IncfiledCriticalBridge Pharma Inc
Priority to MYPI9904300priorityCriticalpatent/MY118384A/en
Publication of MY118384ApublicationCriticalpatent/MY118384A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
DISCLOSED ARE N-SUBSTITUTED HYDROXYALKYL OR CARBOXYALKYLOXYALKYL ANALOGS OF 9-AND/OR 10- OXO-4HBENZO[4,5]CYCLOHEPTA[1 ,2-B]THIOPHENE COMPOUNDS, OR 9-OH AND/OR 10-OH-SUBSTITUTED ANALOGS THEREOF, WHICH POSSESS ANTIHISTAMINIC AND ANTIASTHMATIC PROPERTIES WITH REDUCED SEDATIVE SIDE EFFECTS. THE OPTICALLY ACTIVE ISOMERS AND THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF ARE ALSO DESCRIBED. THE COMPOUNDS WERE ALSO FOUND TO PREVENT SMOOTH MUSCLE HYPERREACTIVITY.
New therapeutic combinations of (S)-2-(benzylaminomethyl)-2,3,8,9,-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders.
Use of condensed 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions treating and preventing diseases related with the inhibition of lipide peroxidation